Aspire Biopharma Holdings Inc's Comment on Supply Chain
The company utilizes contract manufacturers for production and employs personnel with manufacturing experience to manage these relationships. In the fourth quarter of 2024, the company entered into a development and manufacturing agreement with Glatt, which produced sufficient quantities of a high-dose sublingual aspirin product for clinical trials. Glatt has the capability to manufacture the aspirin drug product for potential commercial use; however, their capacity may be insufficient for future requirements, potentially necessitating additional or alternative manufacturers. The company also maintains a fill-and-finish agreement with another contract manufacturer to package the aspirin product produced by Glatt for clinical trials. Both Glatt and the fill-and-finish manufacturer comply with current good manufacturing practice (cGMP) standards. In January 2026, the company entered into a manufacturing agreement with Microsize, a contract development and manufacturing organization (CDMO) based in Quakertown, Pennsylvania, to produce aspirin products for the next phase of clinical trials. Clinical trials using the Glatt-manufactured drug product supported the approval of a section 505(b)(2) New Drug Application (NDA) for the aspirin product, demonstrating faster bioavailability and quicker anti-coagulant effects compared to standard oral aspirin.
Aspire Biopharma Holdings Inc's Comment on Supply Chain
The company utilizes contract manufacturers for production and employs personnel with manufacturing experience to manage these relationships. In the fourth quarter of 2024, the company entered into a development and manufacturing agreement with Glatt, which produced sufficient quantities of a high-dose sublingual aspirin product for clinical trials. Glatt has the capability to manufacture the aspirin drug product for potential commercial use; however, their capacity may be insufficient for future requirements, potentially necessitating additional or alternative manufacturers. The company also maintains a fill-and-finish agreement with another contract manufacturer to package the aspirin product produced by Glatt for clinical trials. Both Glatt and the fill-and-finish manufacturer comply with current good manufacturing practice (cGMP) standards. In January 2026, the company entered into a manufacturing agreement with Microsize, a contract development and manufacturing organization (CDMO) based in Quakertown, Pennsylvania, to produce aspirin products for the next phase of clinical trials. Clinical trials using the Glatt-manufactured drug product supported the approval of a section 505(b)(2) New Drug Application (NDA) for the aspirin product, demonstrating faster bioavailability and quicker anti-coagulant effects compared to standard oral aspirin.
Sources:
Aspire Biopharma Holdings Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Aspire Biopharma Holdings Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
